- Global Pharma News & Resources

Biomarck Pharmaceuticals presents at H.C. Wainwright 2021 Global Life Sciences Conference on March 9-10, 2021

NEWTOWN, Pa.--(BUSINESS WIRE)--#cytokinestorm--Biomarck Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company focused on developing peptides that inhibit MARCKS to treat patients with inflammatory diseases, today announced that Dr. Graham G. Lumsden, president and chief executive officer of Biomarck, will present at the H.C. Wainwright 2021 Global Life Sciences Conference, being held March 9-10, 2021.

The presentation will be available to registered conference attendees for on-demand viewing beginning March 9, 2021 at 7:00 a.m. ET and will also be available in the investor section of the company's website at The webcast will be archived for 60 days following the presentation.

About Biomarck

Biomarck Pharmaceuticals, Ltd. is a clinical stage biotechnology company focused on treating patients with inflammatory and immunological diseases, using our platform of patent-protected peptides that have been developed to inhibit MARCKS. As a critical component of the inflammatory process, MARCKS is responsible for neutrophil aggregation at the site of inflammation and cytokine release. Inhibiting MARCKS with our peptides reduces the adverse effects of inflammation, including acute respiratory distress syndrome (ARDS) and cytokine storm. Phase 2 trials have been completed with our lead peptide, BIO-11006, in ARDS, COPD and NSCLC, confirming safety and efficacy in these three potential indications. In vivo data demonstrate that BIO-11006 and other peptides in the Biomarck pipeline inhibit inflammation in dermatology and ophthalmology models. Potential indications include uveitis, dry eye, atopic dermatitis and psoriasis. Learn more about our platform technology and how we are developing safe and targeted treatments for patients in need at



Sean Leous
+ 1 646-866-4012

Additional Inquiries

Editor Details

  • Company:
    • Businesswire
Last Updated: 08-Mar-2021